MDLA (MDLA) Fair Value & Analysis
Healthcare · ID · Market cap 2.5T IDR
Fair value as of: Jun 25, 2026
Analysis
MDLA (MDLA) currently trades at 204.00 IDR, while our model-based Fair Value estimate is 517.75 IDR — implying the stock looks roughly 153.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories. The company also processes medical device products; and digital platform and web portal activities for human use, as well as pharmaceutical products. In addition, the company develops GoApotik, a B2B2C platform for expanding its products to retailers, end consumers, and patients. PT Medela Potentia Tbk was founded in 2011 and is headquartered in Jakarta Selatan, Indonesia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is MDLA (MDLA) undervalued?
What is the fair value of MDLA?
What is the quality score of MDLA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.